Abstract: In this study, glial cell-derived neurotrophic factor GDNF was used as an evaluation index to explore the effect of dexmedetomidine, a commonly used clinical anesthetic and sedative, on the activation of intestinal glial cells. Rat intestinal glial cells were selected for in vitro experiments, cells were treated with dexmedetomidine at various concentrations for 24 h. The expression of the glial fibrillary acidic protein (GFAP) was determined by immunofluorescence assay. The mRNA and protein levels of GDNF were measured by RT-qPCR and Western Blot, respectively. Immunofluorescence of GFAP results indicated that intestinal glial cells had slender synapses distributed on the edge of the cell body. No differences in GAFP expression were observed between dexmedetomidine treated and untreated cells. However, dexmedetomidine treatment increased the GDNF expression significantly at both mRNA and protein levels in intestinal glial cells. Dexmedetomidine can activate intestinal glial cells and increase the secretion of glial cell-derived neurotrophic factor (GDNF).

Keywords: intestinal glial cells, glial cell-derived neurotrophic factor, dexmedetomidine, intestinal mucosal barrier function

The intestine has the second-largest nervous system in the human body—Enteric nerve system (ENS). The enteric nervous system is distributed throughout the digestive tract and is composed of enteric neuron cells and enteric glial cells (EGC). The number of intestinal glial cells is 4 to 10 times that of intestinal neuronal cells (1, 2). In recent years, more and more evidence has shown that intestinal glial cells not only support enteric neuronal cells but also play a key role in the proliferation and repair of the intestinal epithelium and the maintenance of intestinal mucosal barrier structure and function.

Dexmedetomidine (Dex) is a new type of highly selective α-2 adrenergic receptor agonist with central anti-sympathetic properties, which can play a role in sedation, analgesia, and anti-anxiety. Dexmedetomidine has been applied in clinical anesthesia and is widely used in intensive care and post-operative sedation.

Glia-derived neurotrophic factor (GDNF) is a signal molecule secreted by intestinal glial cells. In this study, rat intestinal glial cells were used for in vitro experiments, and GDNF was used as an evaluation index to study the role of dexmedetomidine in activating intestinal glial cells at the molecular and cellular levels.

METHOD

Cells and reagents

Rat primary intestinal glial cells were obtained from Cybertron Biotechnology (Shanghai, China). TRIzol reagent, cDNA first-strand synthesis kit, SYBR Select Master Mix antibodies specific for GDNF and GFAP were purchased from ThermoFisher (USA). Anti-GAPDH, Tubulin antibodies, and anti-mouse IgG HRP conjugated secondary antibodies were purchased from Cell signaling Technology (CST, USA).

Cytotoxicity assay

1 × 10⁴ cells were cultured in 96-well plates and incubated at 37°C for 24 h. Dexmedetomidine with various concentrations (0-200 μM) was added into cells for 24 h. The cytotoxicity of dexmedetomidine was evaluated by the cell counting kit-8 (CCK8) (Donjindo) following the manufacturer’s instructions. The optical density (OD) value of the wells at...
a wavelength of 450 nm was measured by a microplate reader (Bio-Rad). Relative cell viability rate was determined as described previously (3).

**Dexmedetomidine treatment**

The rat primary intestinal glial cells were seeded into 24-well plates. When cells grew to 70-80% confluency, dexmedetomidine at various concentrations was added into cells and incubated for 24 h. The untreated cells were set as a negative control. All experiments were performed in triplicates.

**Immunofluorescence assays**

At 24 h post dexmedetomidine treatment, cells were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature. Then cells were treated with PBS containing 0.1% Triton X-100 for 10 mins following by blocking with PBS containing 5% FBS for 1h. Subsequently, cells were incubated with a monoclonal antibody against GDNF (1: 100, ThermoFisher) for 1h followed by incubated FITC-conjugated goat anti-mouse IgG (CST). Nuclear staining with DAPI was performed following manufacturer instructions (ThermoFisher). The fluorescence was observed under a Leica DMI4000 B microscope (Leica, Germany).

**Real-Time PCR**

Total RNA was isolated by TRIzol reagent (Life Technologies) and cDNA was synthesized by the Thermo Scientific Revert Aid First Strand cDNA Synthesis Kit (Thermo Scientific) according to the manufacturer’s instruction. Quantitative PCR was performed in triplicates with SYBR Select Master Mix (Applied Biosystems) on the 7500 Real-Time PCR system (Applied Biosystems). The reaction was performed for 94°C for 5 min; 40 cycles of 94°C for 15 s, 60°C for 15 s. The gene expression relative to GAPDH was determined by the $2^{-\Delta\Delta CT}$ method. Primers were summarized in Table 1.

**Western blot**

The intracellular proteins were harvested by RIPA buffer (Life Technologies) and subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membrane (Millipore). The membrane was blocked with 5% nonfat dry milk in TBST, then incubated with the monoclonal antibody against GDNF (1: 3000, ThermoFisher), Tubulin (1: 3000, CST) or GAPDH (1: 3000, CST) overnight at 4°C. Subsequently, the membrane was incubated with the anti-mouse IgG HRP conjugated secondary antibody (1: 5000, CST) for 1 h at room temperature. The bands were developed by BeyoEcl Star Kit (Beyotime, China) and the relative expression of GDNF was expressed as GDNF/GAPDH ratio analyzed by ImageJ software.

**Elisa**

To detect secreted GDNF in the medium, the culture supernatants of cells after 24 h dexmedetomidine treatment were collected. The GDNF content was measured by the GDNF ELISA kit (Abcam, USA) according to the manufacturer’s instructions.

**Statistical analysis**

Data were analyzed using statistical software (SPSS 20; IBM SPSS, USA). Data were presented as mean ± SD. Comparison within the group was analyzed by paired sample t-test. A P value < 0.05 was considered statistically significant.

**RESULTS**

**Cellular toxicity of dexmedetomidine**

To exclude the possibility that cytotoxicity of dexmedetomidine has an impact on cell viability, cytotoxic effects of dexmedetomidine were evaluated by the CCK-8 assay. As shown in Figure 1, dexmedetomidine did not show significant toxicity on rat primary intestinal glial cells up to 100 μM,

| Primer name | Sequence (5’-3’) |
|-------------|-----------------|
| GDNF-F      | GGCGTGACCAGTGACTCCAAT |
| GDNF-R      | GTGCCGCCGCTTGTTTATC |
| GAPDH-F     | AGTGCCAGCCTCGCTCATA |
| GAPDH-R     | ATGAAGGGGTGCTTGTGGC |

Figure 1. Cytotoxic effect of dexmedetomidine on rat primary intestinal glial cells. To determine the cytotoxicity, cells were treated with various concentrations of dexmedetomidine (0-200 μM) for 24 h. Relative cell viability was determined by CCK8 assay and normalized to the value of 0 μM group (set up as 100%). Data are mean ± SD from three independent experiments.
the average cell survival rate was above 90%, and no difference in cell morphology compared with mock-treated cells was observed (data not shown). Therefore, the highest concentration of 100 μM was selected for further experiments.

The effect of dexmedetomidine treatment on GFAP expression

Since intermediate filament proteins—intestinal glial fibrillary acidic protein (GFAP) and calcium-binding protein S100 protein are expressed in intestinal glial cells, the morphology of intestinal glial cells was evaluated by GFAP expression. As shown in Figure 2, no significant differences in GFAP expression were observed between dexmedetomidine-treated cells and control cells. Intestinal glial cells presented clear, continuous, and elongated synapses around the nucleus, distributed at the edge of the cell body, similar in shape to astrocytes in the central nervous system.

GDNF mRNA levels after dexmedetomidine treatment

To evaluate the effect of dexmedetomidine on GDNF mRNA level, intestinal glial cells were treated with different concentrations of dexmedetomidine for 24 h, GDNF mRNA was measured by RT-PCR. As shown in Figure 3, dexmedetomidine treatment increased the GDNF mRNA level in a dose-dependent manner, indicating that dexmedetomidine treatment significantly upregulated GDNF mRNA expression compared to the control group (P < 0.05).

Figure 3. Effect of dexmedetomidine on mRNA expression of GDNF. Data were normalized to values of 0 mM group (set up as 100%). Error bars indicate SD from three independent experiments and statistically significant differences are indicated by asterisks (*P < 0.05, **P < 0.01).

Figure 3A. Effect of dexmedetomidine on GDNF protein expression. (A) The intracellular GDNF was detected by western blot analysis. (B) The secreted GDNF was measured by the GDNF Elisa kit.
Dexmedetomidine enhanced GDNF protein expression

To further characterize dexmedetomidine function on GDNF expression, the intracellular and extracellular expression of GDNF were determined. As shown in Figure 3A, the protein level of GDNF after dexmedetomidine treatment was significantly higher than in the untreated group. The ratio of GDNF to GAPDH was 0.40 ± 0.07 and 0.75 ± 0.12 in dexmedetomidine treated (100 μM) and untreated groups, respectively. In addition, the secreted GDNF was measured by an ELISA kit, the results were in agreement with the observation of intracellular expression. Our results indicated that dexmedetomidine treatment significantly induced both intracellular and extracellular GDNF protein expression.

DISCUSSION

Traumas such as hemorrhage or hemorrhagic shock during surgery cause damage to the intestinal mucosal barrier function (4). The intestinal glial cells play an important regulatory role in the repair of the intestinal mucosal barrier. Intestinal glial cells provide nutrition and support to intestinal epithelial cells. Intestinal glial cells also cause phenotypic changes in the intestinal mucosal barrier by regulating the expression and secretion of neural signal molecules and maintain the integrity of the intestinal mucosal barrier (5).

Intestinal glial cells derived from the neuroectoderm are important components of the enteric nervous system. Intestinal glial cells are mainly distributed in the submucosal plexus of the intestinal wall and the intestinal myenteric plexus (2). Its morphology and function are the same as those of the central nervous system. Similar to astrocytes, glial fibrillary acidic protein (GFAP) and calcium-binding protein S100 are the most commonly used markers of intestinal glial EGC (2). Therefore, we used GFAP as a marker to observe the morphology of intestinal glial cells.

The terminal feet of intestinal glial cells EGC under the mucosa of the intestinal wall are in close contact with intestinal epithelial cells. EGC cells secrete neural signal molecules and regulate the intestinal barrier function through these neural signal molecules. The signal molecules secreted by intestinal glial cells include glial cell-derived neurotrophic factor (GDNF), GSNO (glial-derived s-nitrosoglutathione) (2, 6-9). In the current study, GDNF was selected as the detection index to evaluate the function of dexmedetomidine on activating intestinal glial cells.

Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist. Dexmedetomidine inhibits the release of norepinephrine after activating the receptor and has central anti-sympathetic properties, meanwhile, it exerts sedative, analgesic, and anti-anxiety effects, and does not significantly inhibit breathing (10). Therefore, dexmedetomidine is increasingly used in clinical anesthesia, intensive care, and postoperative sedation. Clinically, the level of serum dexmedetomidine concentration is μmol/L when applied in clinical anesthesia and sedation of critically ill patients. Refer to the dose screening of dexmedetomidine in vitro (11), we further determined the toxicity of dexmedetomidine on rat primary intestinal glial cells, since the cell viability was above 90% when treated with 100 μM of dexmedetomidine. The highest concentration of dexmedetomidine was set as 100 μM in this study.

Our results demonstrated that similar to the morphology of astrocytes in the central nervous system, intestinal glial cells presented long and thin synapses distributed on the edge of the cell body. The dexmedetomidine treatment showed no significant effect on the expression of the intestinal glial fibrillary acidic protein (GFAP). 24 hours post-treatment, the GDNF expression level of intestinal glial cells EGC significantly increased at both mRNA and protein levels, indicating that dexmedetomidine activated intestinal glial cells and the secreted signal molecule GDNF increased dramatically. The previous study demonstrated that intraperitoneal injection of GDNF in genetically mutant rats with intestinal glial cell defects up-regulated the expression of intestinal epithelial cell tight junction proteins ZO-1 and Occludin (6), and significantly reduced the permeability of the rat intestinal mucosal barrier and restored the intestinal mucosal barrier function. In addition, GDNF showed a strong anti-apoptotic effect on intestinal epithelial cells (12). Our results showed that dexmedetomidine activated intestinal glial cells and induced secretion of GDNF. Dexmedetomidine is a commonly used clinical anesthetic and sedative with a protective effect on the intestinal mucosal barrier (13-15). Our in vitro experiments demonstrated that the protective effect of dexmedetomidine on intestinal mucosal barrier damage may be related to the activation of intestinal glial cells to promote GDNF expression. The mechanism of dexmedetomidine activating intestinal glial cells remains unclear. Previous studies have demonstrated that dexmedetomidine promotes the expression of α7-nicotinic acetylcholine receptor (α7-nAChR) in the hippocampus of rats (16). Since α7-nAChR also expresses on intestinal glial cells, we speculate that
dexmedetomidine may activate intestinal glial cells through a cholinergic pathway mediated by this receptor. The specific mechanism needs further confirmation in the future.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (Grant no. 81760348) and the Yunnan health training project of highlevel talents (Grant no. D-2018019).

**Conflict of interest**

The authors declare no conflicts of interest.

**REFERENCE**

1. Ochoa-Cortes F., Turco F., Linan-Rico A., Soghomonyan S., Whitaker E., et al.: Inflamm. Bowel Dis. 22, 433 (2016).
2. Neunlist M., Rolli-Derkinderen M., Latorre R., Van Landeghem L., Coron E., et al.: Gastroenterology 147, 1230 (2014).
3. Cui J., Hie J., Gao M., Zhou H., Chen Y., et al.: Antivir. Ther. 20, 565 (2015).
4. Meng J., Huang Y.C., Huang J., Yang K.: J. Trauma Acute Care Surg. 80, 972 (2016).
5. Aube A.C., Cabarrocas J., Bauer J., Philippe D., Aubert P., et al.: Gut 55, 630 (2006).
6. Savidge T.C., Newman P., Pothoulakis C., Ruhl A., Neunlist M., et al.: Gastroenterology 132, 1344 (2007).
7. Flamant M., Aubert P., Rolli-Derkinderen M., Bourreille A., Neunlist M.R., et al.: Gut 60, 473 (2011).
8. Cheadle G.A., Costantini T.W., Lopez N., Bansal V., Eliceiri B.P., et al.: PLoS One 8, e69042 (2013).
9. Bauman B.D., Meng J., Zhang L., Louiselle A., Zheng E., et al.: J. Surg. Res. 219, 214 (2017).
10. Weerink M.A.S., Struys M.M.R.F., Hannivoort L.N., Barends C.R.M., Absalom A.R., et al.: Clin. Pharmacokinet. 56, 893 (2017).
11. Gao J.D., Sun Z.H., Xiao Z.Y., Du Q., Niu X., et al.: Br. J. Anaesth. 123, 827 (2019).
12. Zhang D.K., He F.Q., Li T.K., Pang X.H., Cui D.J., et al.: J. Pathol. 222, 213 (2010).
13. Zhang X.Y., Liu Z.M., Wen S.H., Li Y.S., Li Y., et al.: Anesthesiology 116, 1035 (2012).
14. Yeh Y.C., Wu C.Y., Cheng Y.J., Liu C.M., Hsiao J.K., et al.: Anesthesiology 125, 355 (2016).
15. Wang Z.X., Huang C.Y., Hua Y.P., Huang W.Q., Deng L.H., et al.: Br. J. Anaesth. 112, 1055 (2014).
16. Xu K.L., Liu X.Q., Yao Y.L., Ye M.R., Han Y.G., et al.: Biochem. Biophys. Res. Commun. 495, 421 (2018).

© 2021 by Polish Pharmaceutical Society. This is an open-access article under the CC BY NC license (http://creativecommons.org/licenses/BY/4.0/).